Skip to content
HowShorted

AMAG PHARMACEUTICALS, INC. short interest in 2018

In 2018, AMAG PHARMACEUTICALS, INC.'s disclosed short interest ran from 23.55% of shares outstanding on 12 Jan 2018 to 26.15% on 31 Dec 2018, a change of +2.60 percentage points. The year's high was 32.92% on 31 Jul 2018 and its low 23.55% on 12 Jan 2018, averaging 28.24% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.70 days on 31 Aug 2018. Full history: AMAG PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for AMAG PHARMACEUTICALS, INC. in 2018

2018 in figures

Start of year
23.55% (12 Jan 2018)
End of year
26.15% (31 Dec 2018)
Change
+2.60 pp
High
32.92% (31 Jul 2018)
Low
23.55% (12 Jan 2018)
Average
28.24%
Highest days to cover
25.70 (31 Aug 2018)
SEC filings marked
10

Every report in 2018

AMAG PHARMACEUTICALS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201823.55%10.00results (8-K)
31 Jan 201823.58%10.23
15 Feb 201826.10%3.98results (8-K)
28 Feb 201827.69%5.86results (8-K)
15 Mar 201828.48%10.3810-K filed
29 Mar 201826.48%9.80
13 Apr 201826.96%11.48
30 Apr 201827.27%18.06
15 May 201828.34%8.95results (8-K), 10-Q filed
31 May 201829.55%19.81
15 Jun 201831.78%11.89
29 Jun 201832.26%11.30
13 Jul 201831.57%23.59
31 Jul 201832.92%20.69
15 Aug 201830.10%17.37results (8-K), 10-Q filed
31 Aug 201829.75%25.70
14 Sep 201829.75%21.55
28 Sep 201826.64%10.94
15 Oct 201826.46%13.04
31 Oct 201828.14%15.04
15 Nov 201829.25%7.74results (8-K), 10-Q filed
30 Nov 201828.31%19.57
14 Dec 201826.79%14.46
31 Dec 201826.15%14.42

See also: AMAG PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.